Adherence to imatinib therapy in patients with gastrointestinal stromal tumors |
| |
| Authors: | Jean-Yves Blay Piotr Rutkowski |
| |
| Affiliation: | 1. Department of Medicine, Centre Léon-Bérard-Claude-Bernard Lyon-1 University, Lyon, France;2. Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland |
| |
| Abstract: | Imatinib mesylate, an oral tyrosine kinase inhibitor, is indicated for first-line treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumors (GIST). Imatinib also is approved as adjuvant therapy for patients following resection of primary GIST. Despite the efficacy of imatinib for the treatment of patients with GIST, adherence to treatment can prove difficult. |
| |
| Keywords: | Gastrointestinal stromal tumors Imatinib Adherence |
| 本文献已被 ScienceDirect 等数据库收录！ |
